Prognostic factors of hematological recovery in life-threatening nonchemotherapy drug-induced agranulocytosis: A study of 91 patients from a single center

Presse Medicale

Volumn 33, Issue 17, 2004, Pages 1164-1168

  Maloisel, Fréderic ^a   Andrès, Emmanuel ^a   Kaltenbach, Georges ^a   Noel, Esther ^a   Martin Hunyadi, Catherine ^a   Dufour, Patrick ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTITHROMBOCYTIC AGENT; ANTITHYROID AGENT; BENZYLTHIOURACIL; CARBAMAZEPINE; CARBIMAZOLE; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CLOZAPINE; DRUG; FLURBIPROFEN; GROWTH FACTOR; HEMOPOIETIC GROWTH FACTOR; IMIPENEM; INDALPINE; MEPRONIZINE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; NORFLOXACIN; PIPERACILLIN; SULFAMETHOXAZOLE; TIAPRIDE; TICLOPIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ADULT; AGED; AGRANULOCYTOSIS; ARTICLE; CONVALESCENCE; DRUG INDUCED AGRANULOCYTOSIS; FEMALE; HEMATOLOGY; HUMAN; INFECTION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; RISK FACTOR; SEPTIC SHOCK; STATISTICAL ANALYSIS;

EID: 5644280254     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0755-4982(04)98884-7     Document Type: Article

References (23)

1. Schute W. Uber eigenartige Halserkrankungen. Dtsch Med Wochensehr 1922; 48: 1495-7.
2. Young NS. Agranulocytosis. JAMA 1994; 271, 935-8.
3. Kaufman DW, Kelly JP, Levy M, Shapiro S. The drug etiology of agranulocytosis: an update of the International Agranulocytosis and Aplastic Anemia Study. Pharmacoepidemiol Drug Safety 1993; 2: 525-9.
4. Van der Klauw MM, Goudsmit R, Halle R et al. A population-based case-cohort study of drug-associated agranulocytosis. Arch Intern Med 1999; 159: 369-74.
5. Paitel JF, Stockemer V, Dorvaux V, Witz F, Guerci A, Lederlin P. Agranulocytoses aigues médicamenteuses. Étude clinique à propos de 30 patients et évolution des étiologies sur 2 décennies. Rev Med Interne 1995; 16: 495-9.
6. Vial T, Pofilet C, Pham E, Payen C, Evreux JC Agranulocytoses aiguēs médicamenteuses: expérience du centre Régional de Pharmacovigilance de Lyon sur 7 ans. Thérapie 1996; 51: 508-15.
7. Andres E, Kurtz JE, Offner C et al. Agranulocytoses mé dicamenteuses: expérience du CHU de Strasbourg. Sem Hop Paris 1998; 74, 1105-10.
8. Julia A, Olona M, Bueno J et al. Drug-induced agranulocytosis: prognostic factors in a series of 168 episodes. Br J Haematol 1991; 79: 366-71.
9. Heimpel H. The drug etiology of agranulocytosis and aplastic anemia. Kauf man DW, Kelly JP, Levy M, Shapiro S. Monographs in epidemiology and biostatics, vol 18. New York: Oxford University Press 1991: 27-38.
10. Ozer H, Armitage JO, Bennett CL et al. 2000 update of recommendations for use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 2000; 18: 3558-85.
11. Andrès E, Maloisel F, Kurtz JE et al. Les facteurs de croissance hématopoīétique ont-ils une place dans le traitement des agranulocytoses médicamenteuses? Rev Med Inteme 2000; 21: 580-5.
12. Andrès E, Noel E, Maloisel F. Nonchemotherapy drug-induced agranulocytosis: interest of hematopoietic growth factors. J Intern Med 2002; 251: 533-4.
13. Sprikkelman A, de Wolf J, Vellenga E. The application of hematopoietic growth factors in drug-induced agranulocytosis. A review of 71 cases. Leukemia 1994; 8: 2031-6.
14. Andres E, Kurtz JE, Perrin AE, Dufour P, Schlienger JL, Maloisel F. The use of haematopoietic growth factors in antithyroid-related drug-induced agranulocytosis: a report of 20 patients. QJM 2001; 94: 423-8.
15. Andres E, Kurtz JE, Martin-Hunyadi C et al. Non-chemotherapy drug-induced agranulocytosis in elderly patients: the effects of Granulocyte Colony-Stimulating Factor. Am J Med 2002; 112: 4604.
16. Dale DC. Neutropenia. Williams WJ, Beuther E, Erslev AJ, Lichtman MA. Hematology. New York: Mc Graw Hill; 1990: 812-7.
17. Bénichou C, Solal-Celigny P. Standardization of definitions and criteria for causality assessment of adverse drug reactions. Drug-induced blood cytopenia: report of an international consensus meeting. Now Rev Fr Hematolol 1993; 33: 257-62.
18. Andrès E, Kurtz JE, Maloisel F. Non-chemotherapy drug-induced agranulocytosis: experience of the Strasbourg teaching hospital (1985-2000) and review of the literature. Clin Lab Haematol 2002; 24: 99-106.
19. Maloisel F, Andrès E, Kaltenbach G, Noel E. Prognostic factors of hematological recovery in nonchemotherapy drug-induced agranulocytosis. Haematologica 2003; 88: 470-1.
20. Collett D. Modelling survival data in medicine research. Londres: Chapman & Hall 1994.
21. Beauchesne MF, Shalansky SJ. Nonchemotherapy drug-induced agranulocytosis: a review of 118 patients treated with colony-stimulating factors. Pharmacotherapy 1999; 19: 299-305.
22. Fukata S, Kuma K, Sugawara M. Granulocyte colony-stimulating factor (G-CSF) does not improve recovery from antithyroid drug-induced agranulocytosis: a prospective study. Thyroid 1999; 9: 29-31.
23. Tajiri J, Noguchi S, Murakami T, Murakami N. Antithyroid drug-induced agranulocytosis. The usefulness of routine white blood cell count monitoring. Arch Intern Med 1990; 150: 621-4.